Iris Lansdorp-Vogelaar

List of Publications by Citations

162 papers	8,620 citations	43 h-index	91 g-index
174 ext. papers	10,689 ext. citations	7.5 avg, IF	5.89 L-index

#	Paper	IF	Citations
162	Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. *New England Journal of Medicine*, **2012**, 366, 687-96	59.2	1934
161	Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. *Cancer*, **2010**, 116, 544-73	6.4	1399
160	Evaluating test strategies for colorectal cancer screening: a decision analysis for the U.S. Preventive Services Task Force. *Annals of Internal Medicine*, **2008**, 149, 659-69	8	420
159	Estimation of Benefits, Burden, and Harms of Colorectal Cancer Screening Strategies: Modeling Study for the US Preventive Services Task Force. *JAMA - Journal of the American Medical Association* , **2016**, 315, 2595-609	27.4	271
158	Increasing incidence of colorectal cancer in young adults in Europe over the last 25 years. *Gut*, **2019**, 68, 1820-1826	19.2	220
157	Cost-effectiveness of colorectal cancer screening. *Epidemiologic Reviews*, **2011**, 33, 88-100	4.1	188
156	Population-Based Colonoscopy Screening for Colorectal Cancer: A Randomized Clinical Trial. *JAMA Internal Medicine*, **2016**, 176, 894-902	11.5	170
155	Effect of rising chemotherapy costs on the cost savings of colorectal cancer screening. *Journal of the National Cancer Institute*, **2009**, 101, 1412-22	9.7	138
154	Public health impact of achieving 80% colorectal cancer screening rates in the United States by 2018. *Cancer*, **2015**, 121, 2281-5	6.4	134
153	Contribution of screening and survival differences to racial disparities in colorectal cancer rates. *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 728-36	4	124
152	Real-Time Monitoring of Results During First Year of Dutch Colorectal Cancer Screening Program and Optimization by Altering Fecal Immunochemical Test Cut-Off Levels. *Gastroenterology*, **2017**, 152, 767-775.e2	13.3	121
151	Faecal immunochemical tests versus guaiac faecal occult blood tests: what clinicians and colorectal cancer screening programme organisers need to know. *Gut*, **2015**, 64, 1327-37	19.2	114
150	Cost-effectiveness of computed tomographic colonography screening for colorectal cancer in the medicare population. *Journal of the National Cancer Institute*, **2010**, 102, 1238-52	9.7	109
149	The impact of the rising colorectal cancer incidence in young adults on the optimal age to start screening: Microsimulation analysis I to inform the American Cancer Society colorectal cancer screening guideline. *Cancer*, **2018**, 124, 2964-2973	6.4	108
148	Comorbidity-adjusted life expectancy: a new tool to inform recommendations for optimal screening strategies. *Annals of Internal Medicine*, **2013**, 159, 667-76	8	100
147	Cost-effectiveness analysis of a quantitative immunochemical test for colorectal cancer screening. *Gastroenterology*, **2011**, 141, 1648-55.e1	13.3	93
146	Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits. *Annals of Internal Medicine*, **2014**, 161, 104-12	8	91

145	Radiation-related cancer risks from CT colonography screening: a risk-benefit analysis. *American Journal of Roentgenology*, **2011**, 196, 816-23	5.4	89
144	A systematic comparison of microsimulation models of colorectal cancer: the role of assumptions about adenoma progression. *Medical Decision Making*, **2011**, 31, 530-9	2.5	81
143	Should colorectal cancer screening be considered in elderly persons without previous screening? A cost-effectiveness analysis. *Annals of Internal Medicine*, **2014**, 160, 750-9	8	76
142	Family history and the natural history of colorectal cancer: systematic review. *Genetics in Medicine*, **2015**, 17, 702-12	8.1	70
141	Sojourn time of preclinical colorectal cancer by sex and age: estimates from the German national screening colonoscopy database. *American Journal of Epidemiology*, **2011**, 174, 1140-6	3.8	69
140	State disparities in colorectal cancer mortality patterns in the United States. *Cancer Epidemiology Biomarkers and Prevention*, **2011**, 20, 1296-302	4	69
139	A novel hypothesis on the sensitivity of the fecal occult blood test: Results of a joint analysis of 3 randomized controlled trials. *Cancer*, **2009**, 115, 2410-9	6.4	64
138	Colorectal cancer deaths attributable to nonuse of screening in the United States. *Annals of Epidemiology*, **2015**, 25, 208-213.e1	6.4	63
137	Adherence to surveillance guidelines after removal of colorectal adenomas: a large, community-based study. *Gut*, **2015**, 64, 1584-92	19.2	60
136	Stool DNA testing to screen for colorectal cancer in the Medicare population: a cost-effectiveness analysis. *Annals of Internal Medicine*, **2010**, 153, 368-77	8	60
135	Cost-effectiveness of one versus two sample faecal immunochemical testing for colorectal cancer screening. *Gut*, **2013**, 62, 727-34	19.2	59
134	Rationale and design of the European Polyp Surveillance (EPoS) trials. *Endoscopy*, **2016**, 48, 571-8	3.4	59
133	Consequences of Increasing Time to Colonoscopy Examination After Positive Result From Fecal Colorectal Cancer Screening Test. *Clinical Gastroenterology and Hepatology*, **2016**, 14, 1445-1451.e8	6.9	57
132	Fecal occult blood testing when colonoscopy capacity is limited. *Journal of the National Cancer Institute*, **2011**, 103, 1741-51	9.7	57
131	Personalizing colonoscopy screening for elderly individuals based on screening history, cancer risk, and comorbidity status could increase cost effectiveness. *Gastroenterology*, **2015**, 149, 1425-37	13.3	56
130	Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a clinical practice guideline. *BMJ, The*, **2019**, 367, l5515	5.9	55
129	Individualizing colonoscopy screening by sex and race. *Gastrointestinal Endoscopy*, **2009**, 70, 96-108, 108.e1-24	5.1	55
128	Exploring the recent trend in esophageal adenocarcinoma incidence and mortality using comparative simulation modeling. *Cancer Epidemiology Biomarkers and Prevention*, **2014**, 23, 997-1006	4	54

127	Variation in Adenoma Detection Rate and the Lifetime Benefits and Cost of Colorectal Cancer Screening: A Microsimulation Model. *JAMA - Journal of the American Medical Association*, **2015**, 313, 2349-58	27.4	51
126	At what costs will screening with CT colonography be competitive? A cost-effectiveness approach. *International Journal of Cancer*, **2009**, 124, 1161-8	7.5	51
125	Impact of colorectal cancer screening on cancer-specific mortality in Europe: A systematic review. *European Journal of Cancer*, **2020**, 127, 224-235	7.5	47
124	Cumulative Burden of Colorectal Cancer-Associated Genetic Variants Is More Strongly Associated With Early-Onset vs Late-Onset Cancer. *Gastroenterology*, **2020**, 158, 1274-1286.e12	13.3	47
123	The value of models in informing resource allocation in colorectal cancer screening: the case of The Netherlands. *Gut*, **2015**, 64, 1985-97	19.2	46
122	Optimizing colorectal cancer screening by race and sex: Microsimulation analysis II to inform the American Cancer Society colorectal cancer screening guideline. *Cancer*, **2018**, 124, 2974-2985	6.4	44
121	Adherence to colorectal cancer screening: four rounds of faecal immunochemical test-based screening. *British Journal of Cancer*, **2017**, 116, 44-49	8.7	43
120	Validation of Models Used to Inform Colorectal Cancer Screening Guidelines: Accuracy and Implications. *Medical Decision Making*, **2016**, 36, 604-14	2.5	43
119	Increasing Incidence of Colorectal Cancer in Adolescents and Young Adults Aged 15-39 Years in Western Australia 1982-2007: Examination of Colonoscopy History. *Frontiers in Public Health*, **2017**, 5, 179	6	43
118	Cost-effectiveness of screening and treating Helicobacter pylori for gastric cancer prevention. *Baillieres Best Practice and Research in Clinical Gastroenterology*, **2013**, 27, 933-47	2.5	42
117	Cost-effectiveness of colorectal cancer screening - an overview. *Baillieres Best Practice and Research in Clinical Gastroenterology*, **2010**, 24, 439-49	2.5	42
116	Cost Effectiveness of Screening Patients With Gastroesophageal Reflux Disease for Barrett's Esophagus With a Minimally Invasive Cell Sampling Device. *Clinical Gastroenterology and Hepatology* , **2017**, 15, 1397-1404.e7	6.9	40
115	Impact of the COVID-19 pandemic on faecal immunochemical test-based colorectal cancer screening programmes in Australia, Canada, and the Netherlands: a comparative modelling study. *The Lancet Gastroenterology and Hepatology*, **2021**, 6, 304-314	18.8	38
114	Incidence of faecal occult blood test interval cancers in population-based colorectal cancer screening: a systematic review and meta-analysis. *Gut*, **2019**, 68, 873-881	19.2	34
113	Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a microsimulation modelling study. *BMJ, The*, **2019**, 367, l5383	5.9	33
112	Clarifying differences in natural history between models of screening: the case of colorectal cancer. *Medical Decision Making*, **2011**, 31, 540-9	2.5	33
111	Trends in Incidence and Stage at Diagnosis of Colorectal Cancer in Adults Aged 40 Through 49 Years, 1975-2015. *JAMA - Journal of the American Medical Association*, **2019**, 321, 1933-1934	27.4	32
110	Harms, benefits and costs of fecal immunochemical testing versus guaiac fecal occult blood testing for colorectal cancer screening. *PLoS ONE*, **2017**, 12, e0172864	3.7	31

109	An Accurate Cancer Incidence in Barrett's Esophagus: A Best Estimate Using Published Data and Modeling. *Gastroenterology*, **2015**, 149, 577-85.e4; quiz e14-5	13.3	30
108	Optimising the expansion of the National Bowel Cancer Screening Program. *Medical Journal of Australia*, **2014**, 201, 456-61	4	30
107	Association Between Concentrations of Hemoglobin Determined by Fecal Immunochemical Tests and Long-term Development of Advanced Colorectal Neoplasia. *Gastroenterology*, **2017**, 153, 1251-1259.e2	13.3	28
106	Comparative economic evaluation of data from the ACRIN National CT Colonography Trial with three cancer intervention and surveillance modeling network microsimulations. *Radiology*, **2011**, 261, 487-98	20.5	28
105	Gender Differences in Fecal Immunochemical Test Performance for Early Detection of Colorectal Neoplasia. *Clinical Gastroenterology and Hepatology*, **2015**, 13, 1464-71.e4	6.9	27
104	How much colonoscopy screening should be recommended to individuals with various degrees of family history of colorectal cancer?. *Cancer*, **2011**, 117, 4166-74	6.4	27
103	Fecal immunochemical test-based colorectal cancer screening: The gender dilemma. *United European Gastroenterology Journal*, **2017**, 5, 448-454	5.3	26
102	Screening for gastric cancer in Western countries. *Gut*, **2016**, 65, 543-4	19.2	25
101	Colorectal Cancer Screening: An Updated Modeling Study for the US Preventive Services Task Force. *JAMA - Journal of the American Medical Association*, **2021**, 325, 1998-2011	27.4	25
100	Productivity savings from colorectal cancer prevention and control strategies. *American Journal of Preventive Medicine*, **2011**, 41, e5-e14	6.1	24
99	Effect of Time to Diagnostic Testing for Breast, Cervical, and Colorectal Cancer Screening Abnormalities on Screening Efficacy: A Modeling Study. *Cancer Epidemiology Biomarkers and Prevention*, **2018**, 27, 158-164	4	24
98	Colorectal Cancer: Cost-effectiveness of Colonoscopy versus CT Colonography Screening with Participation Rates and Costs. *Radiology*, **2018**, 287, 901-911	20.5	23
97	Effects of cancer screening restart strategies after COVID-19 disruption. *British Journal of Cancer*, **2021**, 124, 1516-1523	8.7	23
96	Attendance and diagnostic yield of repeated two-sample faecal immunochemical test screening for colorectal cancer. *Gut*, **2017**, 66, 118-123	19.2	21
95	Outcomes of screening gastroscopy in first-degree relatives of patients fulfilling hereditary diffuse gastric cancer criteria. *Gastrointestinal Endoscopy*, **2018**, 87, 397-404.e2	5.2	21
94	The appropriateness of more intensive colonoscopy screening than recommended in Medicare beneficiaries: a modeling study. *JAMA Internal Medicine*, **2014**, 174, 1568-76	11.5	21
93	Summary statement on screening for prostate cancer in Europe. *International Journal of Cancer*, **2018**, 142, 741-746	7.5	19
92	Multiple rounds of one sample versus two sample faecal immunochemical test-based colorectal cancer screening: a population-based study. *The Lancet Gastroenterology and Hepatology*, **2019**, 4, 622-631	18.8	19

91	Radiofrequency Ablation of Barrett's Esophagus Reduces Esophageal Adenocarcinoma Incidence and Mortality in a Comparative Modeling Analysis. *Clinical Gastroenterology and Hepatology*, **2017**, 15, 1471-1474	6.9	18
90	Cost-effectiveness of a multitarget stool DNA test for colorectal cancer screening of Medicare beneficiaries. *PLoS ONE*, **2019**, 14, e0220234	3.7	18
89	Effects of Increasing Screening Age and Fecal Hemoglobin Cutoff Concentrations in a Colorectal Cancer Screening Program. *Clinical Gastroenterology and Hepatology*, **2016**, 14, 1771-1777	6.9	18
88	Stage distribution of screen-detected colorectal cancers in the Netherlands. *Gut*, **2018**, 67, 1745-1746	19.2	17
87	Cost Effectiveness of Screening Individuals With Cystic Fibrosis for Colorectal Cancer. *Gastroenterology*, **2018**, 154, 556-567.e18	13.3	16
86	Cost-Effectiveness of Risk-Stratified Colorectal Cancer Screening Based on Polygenic Risk: Current Status and Future Potential. *JNCI Cancer Spectrum*, **2020**, 4, pkz086	4.6	16
85	Nonbleeding adenomas: Evidence of systematic false-negative fecal immunochemical test results and their implications for screening effectiveness-A modeling study. *Cancer*, **2016**, 122, 1680-8	6.4	15
84	Cost-effectiveness of High-performance Biomarker Tests vs Fecal Immunochemical Test for Noninvasive Colorectal Cancer Screening. *Clinical Gastroenterology and Hepatology*, **2018**, 16, 504-512.e11	6.9	15
83	Cost-Effectiveness of Personalized Screening for Colorectal Cancer Based on Polygenic Risk and Family History. *Cancer Epidemiology Biomarkers and Prevention*, **2020**, 29, 10-21	4	14
82	Cost Effectiveness of Age-Specific Screening Intervals for People With Family Histories of Colorectal Cancer. *Gastroenterology*, **2018**, 154, 105-116.e20	13.3	14
81	Immunochemical faecal occult blood testing to screen for colorectal cancer: can the screening interval be extended?. *Gut*, **2017**, 66, 1262-1267	19.2	13
80	Assessment of a cancer screening program. *Baillieres Best Practice and Research in Clinical Gastroenterology*, **2015**, 29, 979-85	2.5	13
79	Development of new non-invasive tests for colorectal cancer screening: the relevance of information on adenoma detection. *International Journal of Cancer*, **2015**, 136, 2864-74	7.5	13
78	Optimal colorectal cancer screening in states' low-income, uninsured populations: the case of South Carolina. *Health Services Research*, **2015**, 50, 768-89	3.4	13
77	Adherence to recommendations of Barrett's esophagus surveillance guidelines: a systematic review and meta-analysis. *Endoscopy*, **2020**, 52, 17-28	3.4	13
76	Comparing the Cost-Effectiveness of Innovative Colorectal Cancer Screening Tests. *Journal of the National Cancer Institute*, **2021**, 113, 154-161	9.7	13
75	Equivalent Accuracy of 2 Quantitative Fecal Immunochemical Tests in Detecting Advanced Neoplasia in an Organized Colorectal Cancer Screening Program. *Gastroenterology*, **2018**, 155, 1392-1399.e3	13.3	13
74	Do Men and Women Need to Be Screened Differently with Fecal Immunochemical Testing? A Cost-Effectiveness Analysis. *Cancer Epidemiology Biomarkers and Prevention*, **2017**, 26, 1328-1336	4	12

73	Incidence of Interval Colorectal Cancer After Negative Results From First-Round Fecal Immunochemical Screening Tests, by Cutoff Value and Participant Sex and Age. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 1493-1500	6.9	12
72	Cost-effectiveness and budget impact analyses of a colorectal cancer screening programme in a high adenoma prevalence scenario using MISCAN-Colon microsimulation model. *BMC Cancer*, **2018**, 18, 464	4.8	11
71	A cost-effectiveness analysis of online, radio and print tobacco control advertisements targeting 25-39 year-old males. *Australian and New Zealand Journal of Public Health*, **2014**, 38, 270-4	2.3	11
70	The second round of the Dutch colorectal cancer screening program: Impact of an increased fecal immunochemical test cut-off level on yield of screening. *International Journal of Cancer*, **2020**, 147, 1098-1106	7.5	11
69	Optimizing Management of Patients With Barrett's Esophagus and Low-Grade or No Dysplasia Based on Comparative Modeling. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 1961-1969	6.9	11
68	Value Of Waiving Coinsurance For Colorectal Cancer Screening In Medicare Beneficiaries. *Health Affairs*, **2017**, 36, 2151-2159	7	10
67	Cost-effectiveness of surveillance schedules in older adults with non-muscle-invasive bladder cancer. *BJU International*, **2019**, 123, 307-312	5.6	10
66	State disparities in colorectal cancer rates: Contributions of risk factors, screening, and survival differences. *Cancer*, **2015**, 121, 3676-83	6.4	10
65	Cost-Savings to Medicare From Pre-Medicare Colorectal Cancer Screening. *Medical Care*, **2015**, 53, 630-8	3.1	9
64	Colonoscopy-Related Mortality in a Fecal Immunochemical Test-Based Colorectal Cancer Screening Program. *Clinical Gastroenterology and Hepatology*, **2021**, 19, 1418-1425	6.9	9
63	The national FIT-based colorectal cancer screening program in the Netherlands during the COVID-19 pandemic. *Preventive Medicine*, **2021**, 151, 106643	4.3	9
62	Costs and outcomes of Lynch syndrome screening in the Australian colorectal cancer population. *Journal of Gastroenterology and Hepatology (Australia)*, **2018**, 33, 1737-1744	4	8
61	The impact of stratifying by family history in colorectal cancer screening programs. *International Journal of Cancer*, **2015**, 137, 1119-27	7.5	8
60	Participation in faecal immunochemical testing-based colorectal cancer screening programmes in the northwest of Europe. *Journal of Medical Screening*, **2020**, 27, 68-76	1.4	8
59	Calibrating Parameters for Microsimulation Disease Models: A Review and Comparison of Different Goodness-of-Fit Criteria. *Medical Decision Making*, **2016**, 36, 652-65	2.5	8
58	Colorectal Cancer Screening in the Novel Coronavirus Disease-2019 Era. *Gastroenterology*, **2020**, 159, 1998-2003	13.3	7
57	Developing a score chart to improve risk stratification of patients with colorectal adenoma. *Endoscopy*, **2016**, 48, 563-70	3.4	7
56	High-Intensity Versus Low-Intensity Surveillance for Patients With Colorectal Adenomas: A Cost-Effectiveness Analysis. *Annals of Internal Medicine*, **2019**, 171, 612-622	8	7

55	Performance of two faecal immunochemical tests for the detection of advanced neoplasia at different positivity thresholds: a cross-sectional study of the Dutch national colorectal cancer screening programme. *The Lancet Gastroenterology and Hepatology*, **2019**, 4, 111-118	18.8	7
54	Calculation of Stop Ages for Colorectal Cancer Screening Based on Comorbidities and Screening History. *Clinical Gastroenterology and Hepatology*, **2021**, 19, 547-555	6.9	7
53	Modeling in Colorectal Cancer Screening: Assessing External and Predictive Validity of MISCAN-Colon Microsimulation Model Using NORCCAP Trial Results. *Medical Decision Making*, **2018**, 38, 917-929	2.5	7
52	Colorectal cancer surveillance in Hodgkin lymphoma survivors at increased risk of therapy-related colorectal cancer: study design. *BMC Cancer*, **2017**, 17, 112	4.8	6
51	Cost-effectiveness of Active Identification and Subsequent Colonoscopy Surveillance of Lynch Syndrome Cases. *Clinical Gastroenterology and Hepatology*, **2020**, 18, 2760-2767.e12	6.9	6
50	Results of a health systems approach to identify barriers to population-based cervical and colorectal cancer screening programmes in six European countries. *Health Policy*, **2018**, 122, 1206-1211	3.2	6
49	Impact of adenoma detection on the benefit of faecal testing vs. colonoscopy for colorectal cancer. *International Journal of Cancer*, **2017**, 141, 2359-2367	7.5	5
48	Utilization of surveillance after polypectomy in the medicare population--a cohort study. *PLoS ONE*, **2014**, 9, e110937	3.7	5
47	Evaluation of new technologies for cancer control based on population trends in disease incidence and mortality. *Journal of the National Cancer Institute Monographs*, **2013**, 2013, 117-23	4.8	5
46	Cost effectiveness of surveillance for GI cancers. *Baillieres Best Practice and Research in Clinical Gastroenterology*, **2016**, 30, 879-891	2.5	5
45	The health impact of human papillomavirus vaccination in the situation of primary human papillomavirus screening: A mathematical modeling study. *PLoS ONE*, **2018**, 13, e0202924	3.7	5
44	The Impact of Uncertainty in Barrett's Esophagus Progression Rates on Hypothetical Screening and Treatment Decisions. *Medical Decision Making*, **2015**, 35, 726-33	2.5	4
43	Modeling costs and benefits of the organized colorectal cancer screening programme and its potential future improvements in Hungary. *Journal of Medical Screening*, **2021**, 28, 268-276	1.4	4
42	Validation of Colorectal Cancer Models on Long-term Outcomes from a Randomized Controlled Trial. *Medical Decision Making*, **2020**, 40, 1034-1040	2.5	4
41	Cost-effectiveness of prevention and early detection of gastric cancer in Western countries. *Baillieres Best Practice and Research in Clinical Gastroenterology*, **2021**, 50-51, 101735	2.5	4
40	Yield of Surveillance Colonoscopies 1 Year After Curative Surgical Colorectal Cancer Resections. *Clinical Gastroenterology and Hepatology*, **2019**, 17, 2285-2293	6.9	3
39	Colorectal cancer screening in Australia. *Lancet Public Health, The*, **2017**, 2, e304-e305	22.4	3
38	Integrating personalised genomics into risk stratification models of population screening for colorectal cancer. *Australian and New Zealand Journal of Public Health*, **2017**, 41, 3-4	2.3	3

37	Cost-Effectiveness of Screening Individuals With Cystic Fibrosis for Colorectal Cancer. *Gastroenterology*, **2017**,	13.3	3
36	Quality Monitoring of a FIT-Based Colorectal Cancer Screening Program. *Clinical Chemistry*, **2019**, 65, 419-426	5.5	3
35	Cost-effectiveness analysis of colorectal cancer screening in a low incidence country: The case of Saudi Arabia. *Saudi Journal of Gastroenterology*, **2021**, 27, 208-216	3	3
34	Colorectal cancer incidence, mortality, tumour characteristics, and treatment before and after introduction of the faecal immunochemical testing-based screening programme in the Netherlands: a population-based study. *The Lancet Gastroenterology and Hepatology*, **2021**,	18.8	2
33	Impact of COVID-19 and suspension of colorectal cancer screening on incidence and stage distribution of colorectal cancers in the Netherlands.. *European Journal of Cancer*, **2021**, 161, 38-43	7.5	2
32	Identifying key factors for the effectiveness of pancreatic cancer screening: A model-based analysis. *International Journal of Cancer*, **2021**, 149, 337-346	7.5	2
31	The EU-TOPIA evaluation tool: An online modelling-based tool for informing breast, cervical, and colorectal cancer screening decisions in Europe. *Preventive Medicine Reports*, **2021**, 22, 101392	2.6	2
30	Development and Validation of Three Regional Microsimulation Models for Predicting Colorectal Cancer Screening Benefits in Europe. *MDM Policy and Practice*, **2021**, 6, 2381468320984974	1.5	2
29	The Impact of the Policy-Practice Gap on Costs and Benefits of Barrett‘s Esophagus Management. *American Journal of Gastroenterology*, **2020**, 115, 1026-1035	0.7	1
28	Optimizing Patient Risk Stratification for Colonoscopy Screening and Surveillance of Colorectal Cancer: The Role for Linked Data. *Frontiers in Public Health*, **2017**, 5, 234	6	1
27	Optimizing screening with faecal immunochemical test for both sexes - Cost-effectiveness analysis from Finland.. *Preventive Medicine*, **2022**, 106990	4.3	1
26	Disability-Adjusted Life Years Averted Versus Quality-Adjusted Life Years Gained: A Model Analysis for Breast Cancer Screening. *Value in Health*, **2021**, 24, 353-360	3.3	1
25	Measures of longitudinal adherence to fecal-based colorectal cancer screening: Literature review and recommended approaches. *International Journal of Cancer*, **2021**, 149, 316-326	7.5	1
24	Surveillance Cessation for Barrett‘s Esophagus: A Survey of Gastroenterologists. *American Journal of Gastroenterology*, **2021**, 116, 1730-1733	0.7	1
23	Modeling Strategies to Optimize Cancer Screening in USPSTF Guideline-Noncompliant Women. *JAMA Oncology*, **2021**, 7, 885-894	13.4	1
22	The impact of information about different absolute benefits and harms on intention to participate in colorectal cancer screening: A think-aloud study and online randomised experiment. *PLoS ONE*, **2021**, 16, e0246991	3.7	1
21	Risk-stratified strategies in population screening for colorectal cancer. *International Journal of Cancer*, **2022**, 150, 397-405	7.5	1
20	Cost-effectiveness of prophylactic hysterectomy in first-degree female relatives with Lynch syndrome of patients diagnosed with colorectal cancer in the United States: a microsimulation study. *Cancer Medicine*, **2021**, 10, 6835-6844	4.8	1

19	Optimising colorectal cancer screening in Shanghai, China: a modelling study.. *BMJ Open*, **2022**, 12, e048156	3	1
18	Different modalities for colorectal cancer screening: experiences in The Netherlands so far. *Colorectal Cancer*, **2016**, 5, 9-19	0.8	0
17	An Evolutionary Algorithm to Personalize Stool-Based Colorectal Cancer Screening.. *Frontiers in Physiology*, **2021**, 12, 718276	4.6	0
16	Colorectal Cancer Screening in Young Adults. *Annals of Internal Medicine*, **2021**, 174, 1039-1040	8	0
15	Diagnostic yield of colonoscopy surveillance in testicular cancer survivors treated with platinum-based chemotherapy: study protocol of a prospective cross-sectional cohort study. *BMC Gastroenterology*, **2021**, 21, 67	3	0
14	Impact of assumptions on future costs, disutility and mortality in cost-effectiveness analysis; a model exploration. *PLoS ONE*, **2021**, 16, e0253893	3.7	0
13	Socioeconomic differences in participation and diagnostic yield within the Dutch national colorectal cancer screening programme with faecal immunochemical testing.. *PLoS ONE*, **2022**, 17, e0264067	3.7	0
12	COVID-19 and Cancer Global Modelling Consortium (CCGMC): A global reference to inform national recovery strategies.. *Journal of Cancer Policy*, **2022**, 32, 100328	1	0
11	Colorectal Cancer Screening within Colonoscopy Capacity Constraints: Can FIT-Based Programs Save More Lives by Trading off More Sensitive Test Cutoffs against Longer Screening Intervals?. *MDM Policy and Practice*, **2022**, 7, 23814683221097064	1.5	0
10	Response to the letter to the editor by Hassan et al.: The diminutive lesion versus the advanced adenoma: Which is the real target of CT colonography screening?. *International Journal of Cancer*, **2009**, 125, 1239-1240	7.5	
9	Comparative benefit and cost-effectiveness of mailed-out faecal immunochemical tests vs collection at the general practitioner. *Alimentary Pharmacology and Therapeutics*, **2021**, 53, 1118-1125	6.1	
8	Interpretation and adherence to the updated risk-stratified guideline for colonoscopy surveillance after polypectomy - a nationwide survey. *Endoscopy International Open*, **2020**, 8, E1405-E1413	3	
7	Intensity of Surveillance for Patients With Colorectal Adenomas. *Annals of Internal Medicine*, **2020**, 172, 442	8	
6	The impact of colorectal cancer screening on incidence and stage IV disease in the Netherlands.. *Journal of Clinical Oncology*, **2021**, 39, 3531-3531	2.2	
5	Using Patient Preferences to Determine Noninferiority Margins in Trials. *JAMA - Journal of the American Medical Association*, **2019**, 322, 2137-2138	27.4	
4	Reply. *Clinical Gastroenterology and Hepatology*, **2021**,	6.9	
3	A restricted look at CRC screening: not considering annual stool testing as an option. *American Journal of Managed Care*, **2016**, 22, e270-4	2.1	
2	Urban density differences in colorectal cancer screening participation and screening yield in The Netherlands. *Preventive Medicine Reports*, **2022**, 27, 101791	2.6	

List of Publications

1	A personalized and dynamic risk estimation model: The new paradigm in Barrett's esophagus surveillance.. *PLoS ONE*, **2022**, 17, e0267503	3.7